Log In
BCIQ
Print this Print this
 

h8F4

  Manage Alerts
Collapse Summary General Information
Company University of Texas MD Anderson Cancer Center
DescriptionHumanized mAb that targets PR1, a short peptide from proteinase 3 (PRTN3; PR3) and neutrophil elastase (NE; ELA-2), when presented by the major histocompatibility complex class I A (HLA-A) allele HLA-A2
Molecular Target Neutrophil elastase (ELANE) (NE) (HLE)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat acute myelogenous leukemia (AML)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$26.0M

0

0


 Deals Details
Get a free BioCentury trial today